- Home
- TGTX
TGTX
TG Therapeutics Inc.
as 09-16-2025 4:00pm EST
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 4.2B | IPO Year: | 1995 |
| Target Price: | $42.50 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | -43.55 |
| 52 Week Low/High: | $21.16 - $46.48 | Next Earning Date: | 11-03-2025 |
| Revenue: | $454,069,000 | Revenue Growth: | 30.96% |
| Revenue Growth (this year): | 82.58% | Revenue Growth (next year): | 44.99% |
Stock Insider Trading Activity of TG Therapeutics Inc. (TGTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lonial Sagar | TGTX | Director | Sep 11 '25 | Sell | $32.24 | 20,852 | $672,268.48 | 94,061 |
Latest TG Therapeutics Inc. News
TGTX Breaking Stock News: Dive into TGTX Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Tg Therapeutics Insider Sold Shares Worth $672,268, According to a Recent SEC Filing
GlobeNewswire
7 days ago
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
GlobeNewswire
9 days ago
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
Simply Wall St.
10 days ago
Why TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback Program
Simply Wall St.
2 months ago
High Growth Tech Stocks to Watch in the US July 2025
Simply Wall St.
2 months ago
Exploring High Growth Tech Stocks in the US This July 2025
Simply Wall St.
2 months ago
High Growth Tech Stocks In The US Market
Simply Wall St.
2 months ago
High Growth Tech Stocks In The US For July 2025
Compare TGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TGTX TG Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.